Compare Summit Therapeutics Inc (SMMT) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.51. Which is the better fit depends on your goals.
| SMMT | USIG | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Fixed Income |
52-Week High | $29.32 | $52.69 |
52-Week Low | $13.05 | $50.50 |
Enterprise Value | $9.90B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
